An overview of psychiatric symptoms in Huntington's disease.

被引：31

作者：

Anderson K.E. ^{[1
]}

Marder K.S. ^{[1
]}

机构：

[1] Gertrude H. Sergievsky Center, Columbia University, 630 West 168th Street, New York, 10032, NY

来源：

Current Psychiatry Reports | 2001年 / 3卷 / 5期

关键词：

Clozapine; Risperidone; Olanzapine; Psychiatric Symptom; Buspirone;

D O I：

10.1007/s11920-996-0030-2

中图分类号：

学科分类号：

摘要：

Huntington's disease (HD) is an inherited autosomal dominant disorder characterized by neurologic, cognitive, and psychiatric symptomatology. Psychiatric symptoms in HD are often amenable to treatment, and relief of these symptoms may provide significant improvement in quality of life. This review will briefly describe neurologic, neuropsychologic and brain imaging data, and then review psychiatric syndromes seen in HD and their treatment.

引用

页码：379 / 388

页数：9

共 243 条

[1]

Harper PS(1992)The epidemiology of Huntington’s disease Hum Gen 89 365-376

[2]

Shiwach R(1994)Psychopathology in Huntington’s disease patients Acta Psychiatr Scand 90 241-246

[3]

Kremer B(1993)A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes Cell 72 971-983

[4]

Goldberg P(1994)A worldwide study of the Huntington’s disease mutation N Engl J Med 330 1401-1406

[5]

Andrew S(1993)The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease Nat Gen 4 398-403

[6]

Andrew S(1995)Early loss of neostriatal striosome neurons in Huntington’s disease J Neuropathol Exp Neurol 54 105-120

[7]

Goldberg P(1995)Striatal D1 and D2 receptor binding in patients with Huntington’s disease and other choreas: a PET study Brain 118 689-696

[8]

Kremer B(1997)PET study of pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease Brain 120 503-514

[9]

Hedreen JC(1999)Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial Neurology 53 1000-1011

[10]

Folstein SE(1989)A controlled clinical trial of baclofen as protective therapy in early Huntington’s disease Ann Neurol 25 252-259

← 1 2 3 4 5 6 7 8 9 10 →